201 related articles for article (PubMed ID: 22697594)
1. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives.
Kalantzi KI; Tsoumani ME; Goudevenos IA; Tselepis AD
Expert Rev Clin Pharmacol; 2012 May; 5(3):319-36. PubMed ID: 22697594
[TBL] [Abstract][Full Text] [Related]
2. [Thrombocyte receptors: current views and therapeutic options].
Peters RJ; Moons AH; Büller HR
Ned Tijdschr Geneeskd; 1999 Sep; 143(39):1952-7. PubMed ID: 10526614
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Konstantopoulos K; Mousa SA
Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
[TBL] [Abstract][Full Text] [Related]
4. Platelet function testing and implications for clinical practice.
Collet JP; Montalescot G
J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
[TBL] [Abstract][Full Text] [Related]
5. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
6. Platelet activation and progression to complications.
Kereiakes DJ; Michelson AD
Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
8. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
9. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
10. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet drugs.
De Meyer SF; Vanhoorelbeke K; Broos K; Salles II; Deckmyn H
Br J Haematol; 2008 Aug; 142(4):515-28. PubMed ID: 18513285
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet activity of L-sulforaphane by regulation of platelet activation factors, glycoprotein IIb/IIIa and thromboxane A2.
Oh CH; Shin JI; Mo SJ; Yun SJ; Kim SH; Rhee YH
Blood Coagul Fibrinolysis; 2013 Jul; 24(5):498-504. PubMed ID: 23412354
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of platelet activation and development of antiplatelet agents].
Cazenave JP; Gachet C; Lanza F
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
Coccheri S
Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498
[TBL] [Abstract][Full Text] [Related]
15. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
16. Platelets and antiplatelet therapy in patients with diabetes mellitus.
Arjomand H; Roukoz B; Surabhi SK; Cohen M
J Invasive Cardiol; 2003 May; 15(5):264-9. PubMed ID: 12730635
[TBL] [Abstract][Full Text] [Related]
17. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Gurbel PA
Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
19. The genetics of antiplatelet drug resistance.
Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
[TBL] [Abstract][Full Text] [Related]
20. Clinical importance of antiplatelet drugs in cardiovascular diseases.
Papp J; Kenyeres P; Toth K
Clin Hemorheol Microcirc; 2013; 53(1-2):81-96. PubMed ID: 22954637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
